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Summary 
Mutations affecting the expression of the Janus family kinase JAK3 were recently shown to be 
responsible for autosomal recessive  severe combined immunodeficiency (SCID). JAK3-defi- 
cient patients present with a clinical phenotype virtually indistinguishable from boys affected by 
X-linked SCID, a disease caused by genetic defects of the common gamma chain (%) that is a 
shared component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15. The specific interac- 
tion of  JAK3 and ~/c represents the biochemical basis for the similarities between these two im- 
munodeficiencies. Both forms of SCID are characterized by recurrent, severe infections lead- 
ing to death in infancy unless successfully treated by allogeneic bone marrow transplantation. 
Because of the potentially lethal complications associated with allogeneic bone marrow trans- 
plantation and the frequent lack of suitable marrow donors, the development of alternative 
forms of therapy is highly desirable.  To this end, we investigated a retroviral-mediated gene 
correction approach for JAK3-deficiency. A vector carrying a copy ofJAK3 cDNA was con- 
structed and used to transduce B  cell lines  derived from patients with JAK3-deficient SCID. 
We demonstrate restoration of  JAK3 expression and phosphorylation upon IL-2 and IL-4 stim- 
ulation. Furthermore, patients' cells transduced with JAK3 acquired the ability to proliferate 
normally in response to IL-2. These data indicate that the biological defects of JAK3-deficient 
cells can be efficiently corrected in vitro by retroviral-mediated gene transfer,  thus providing 
the basis for future investigation of gene therapy as treatment for JAK3-deficient SCID. 
J 
anus kinases (JAK1, JAK2, TYK2, and the recently iden- 
tified JAK3) are a family of nonreceptor protein tyrosine 
kinases  involved in intracellular signal  transduction medi- 
ated by various cytokines, interferons, and growth factors 
(1, 2). JAK3, unlike the other Janus kinase family members, 
has an expression pattern restricted to lymphoid and my- 
eloid tissues (3), and appears  to play a critical role in cyto- 
kine signaling through specific  association with the com- 
mon  gamma  chain  (%)  of the  receptors  for  IL-2,  IL-4, 
IL-7, IL-9, and IL-15 (4-11). JAK3 is activated and phos- 
phorylated upon ligand binding to ~/c-containing receptors 
(12-14),  an  event  leading to  phosphorylation of several 
other proteins (including JAK1 and signal transducers and 
activators of transcription  [STATs]),  and eventually gene 
activation (15). 
F. Candotti  and S.A. Oakes contributed  equally  to this work. 
Several  lines  of evidence have recently underscored the 
biological relevance of  JAK3 and its interaction with % for 
development  and  maturation  of lymphoid tissues.  First, 
mutations in %  have been  shown to  result  in  X-linked 
SCID (XSCID)  (16,  17), a congenital defect of immunity 
typically characterized by severe T  cell lymphopenia, non- 
functional B  cells,  hypoplastic lymphoid organs,  and ex- 
treme susceptibility to  opportunistic infections leading to 
death early in life  (18).  Subsequent studies demonstrated 
that % mutations responsible for "classical" XSCID pheno- 
type resulted in complete disruption of %-JAK3  interac- 
tion, while a specific point mutation in % associated with a 
milder form of combined immunodeficiency was shown to 
result in a severely diminished, but not completely abro- 
gated, association of  JAK3 with % (11). From this evidence 
it was  postulated that mutations affecting JAK3  function 
could produce an autosomal form of inherited immunode- 
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in agreement with this prediction, two independent groups 
identified  genetic  defects  of JAK3  in  patients  affected  by 
a congenital  form of immunodeficiency with  cellular  and 
biological  characteristics  virtually  identical  to  those  seen 
in XSCID,  but  transmitted  as  an  autosomal  recessive  trait 
(19, 20). 
After the original reports, additional SCID patients carry- 
ing abnormalities of  JAK3 expression were identified (Not- 
arangelo,  L.D.,  unpublished  observations),  defining JAK3- 
deficient SCID (JAK3-SCID) as a separate nosological entity. 
On the other hand, because of the clinical similarities exist- 
ing between JAK3-SCID and XSCID (19,  20),  the medi- 
cal management is identical for both forms ofimmunodefi- 
ciency, and allogeneic bone marrow transplantation  (BMT) 
is currently the only curative treatment available.  BMT, how- 
ever,  is  an intensive  procedure  potentially  associated with 
severe  complications  such  as  graft  versus  host  reactions 
(GVHD)  (21),  and is not an available option for many pa- 
tients because of lack of suitable marrow donors.  For these 
reasons,  the  investigation  of alternative  therapeutic  strate- 
gies is needed,  and the  development  of gene-based  thera- 
pies  would be  beneficial  for those  cases  where  traditional 
treatment is not available. 
To investigate a gene therapy approach for JAK3-SCID, 
we  constructed  a  retroviral  vector  containing  the  normal 
JAK3 cDNA sequence  and used it to reconstitute  the  ex- 
pression  of  JAK3 protein in B  cell lines from JAK3-SCID 
patients.  We show that the transgenic JAK3 was expressed 
at  levels  comparable  to  those  found in B  lymphoblastoid 
cells from normal donors. Further, we show that the newly 
expressed JAK3 kinase was phosphorylated upon IL-2 and 
IL-4 stimulation,  and that IL-2-mediated cell proliferation 
was  restored  to  nearly  normal  levels  in JAK3-transduced 
cells.  This study demonstrates  that biological functions af- 
fected in JAK3-deficient cells  can be corrected in vitro by 
retroviral-mediated  gene transfer and suggests the potential 
application ofgene transfer as therapy forJAK3-SCID. 
"micro ping-pong" technique  (26) from PA317 and GP+E-86 
cells and used to infect the gibbon-ape leukemia virus  (GALV)- 
based  PG13  packaging line.  PG13-derived  viral  particles  were 
then used  for subsequent  transduction of  JAK3-SCID as previ- 
ously described  (27). Transfected and transduced cells were sub- 
jected to selection with 0.8-1.0 mg/ml of the neomycin analogue 
G418 (Geneticin;  Life Technologies). 
Western Protein Analysis.  Cells were lysed in buffer containing 
300 mM NaC1,  50 mM Tris-HCl,  2 mM EDTA, 0.5% Triton 
X-100, 2.5 p~M p-nitrophenyl p "guanidino-benzoate, 10 p~g/ml 
aprotinin,  and  10 ~g/ml leupeptin.  Lysates (100  I.zg of protein) 
were centrifuged  at 12,000 g, boiled,  subjected to 8% SDS-PAGE, 
and  electro-transferred  onto  nylon  membranes  (Immobilon-P; 
Millipore,  Bedford, MA). Membranes were incubated with a rab- 
bit polyclonal Ab directed against the COOH terminus of  JAK3 
0x-JAK3) (3) or a mouse monoclonal Ab specific forJAK1 (oe-JAK1; 
Transduction Laboratories,  Lexington, KY) following previously 
reported procedures (12). 
Immunoprecipitation.  Cells  (5-10 X 107) were cultured in RPMI 
1640 without FBS for 4 h, stimulated  with IL-2 (1,000 U/m/) or 
IL-4 (1,000  U/ml)  for 15 min,  and then lysed in the above de- 
fined lysis buffer supplemented with 200 p~M sodium orthovana- 
date.  After centrifugation,  postnuclear supernatants  were immu- 
noprecipitated with c~-JAK3, washed,  boiled,  and resolved  using 
SDS-PAGE electrophoresis.  Immunoprecipitated complexes  were 
immunoblotted  with  anti-phosphotyrosine  mouse  monoclonal 
Ab (o~-PY, 4G10; Upstate Biotechnology Inc., Lake Placid,  NY) 
or o~-JAK3 as described  (12). Detection was then performed by 
enhanced chemiluminescence (ECL; Amersham Corp., Arlington 
Heights,  IL). 
Proliferative Response to IL-2.  Cells  were  incubated in RPMI 
1640 supplemented with 0.5% FBS for 24 h. Cells (2 ￿  104/well) 
were then plated  onto 96-well plates  and incubated for 24 h in 
RPMI with or without 2.5-5 X 10 -7 M IL-2. Tridated thymidine 
([3H]-Tdr,  1 ~Ci/well;  NEN-Dupont,  Boston,  MA)  was  then 
added to microcultures and incubated for an additional  6 h. Cells 
were harvested  with an automated cell harvester  (XVallac, Upp- 
sala, Sweden)  and transferred  to filters. DNA-incorporated radio- 
activity  was determined using a liquid scintillation  counter. 1Le- 
suits are given as average  of six replicates.  Stimulation index was 
calculated as the ratio of [3H]-Tdr incorporated in the presence of 
RPMI medium supplemented with IL-2 divided by that incorpo- 
rated in RPMI medium without IL-2 supplementation. 
Materials and Methods 
Patients and Cell Lines.  C.M.  and  C.A.  are JAK3-SCID sib- 
lings from consanguineous  parents whose mutation has been previ- 
ously reported (19). Peripheral  blood was obtained upon parental 
informed consent from both patients  and normal donors and B 
cell lines (BCLs) were established by standard  Epstein-Barr virus 
immortalization. Cells were maintained in RPMI 1640 (GIBCO 
BRL, Gaithersburg,  MD), and cultured at 37~  5% CO  2. PA317 
(22),  PG13  (23), and  GP+E-86  (24) retrovirus-packaging lines 
were cultured in Dulbecco's modified Eagle's minimum essential 
medium (DME; Biofluids,  Ikockville, MD),  at 37~  10% CO  2. 
All tissue  culture media were supplemented with  10% fetal bo- 
vine  serum  (FBS; Hyclone,  Logan,  UT),  2  mM  L-glutamine 
(GIBCO  BRL),  and  50  txg/ml  gentamycin  (Bio-Whittaker, 
Walkersviile,  MD). 
Retroviral Construct and Transduction Procedures.  A  copy of JAK3 
cDNA (3) was subcloned using the Not/and SnaBI sites into the 
pSAM-EN retroviral  cassette by standard molecular biology tech- 
niques  (25).  Amphotropic  supernatants  were  produced  by  the 
Results  and Discussion 
Retroviral-mediated Expression of  JAK3.  A  3.5-kb  fragment 
containing  the  full-length JAK3  open  reading  frame  was 
subcloned into pSAM-EN retroviral  cassette  to obtain the 
pGCJ3 vector (Fig.  1). This vector was packaged into GALV 
envelope expressing retroviral particles using the PG13 pack- 
aging cell line since this envelope protein  results in higher 
rates  of retroviral  transduction  of lymphoid cells  (28).  Su- 
pernatants  containing retroviral particles were then used to 
transduce JAK3-deficient  BCLs  by  exposure  for  24  h  in 
presence of 10 p,g/ml protamine. After G418 selection, the 
transduced cells were assessed  for JAK3 protein expression. 
Fig. 2  (upper panel)  shows the results of Western analysis on 
whole cell lysates obtained from normal BCLs (lane  1), pa- 
tients  C.M.  and  C.A.  before  (lanes  2  and  5,  respectively) 
and  after  transduction  with  GCJ3  (lanes  4  and  6,  respec- 
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Figure 1.  Schematic  represen- 
tation  of  the  GCJ3 retroviral 
vector. The 3.5-kb JAK3 cDNA 
was  subcloned into  the  Molo- 
ney  murine  leukemia  virus 
(MMLV)-based SAM-EN retro- 
viral cassette that contains the in- 
ternal ribosomal entry sequence 
from  the  encephalomyocarditis 
virus  (EMC)  and the neomycin 
resistance  gene  (neo).  The 
MMLV splice donor  site (SD) 
and the spfice acceptor site (SA) 
in the 3' terminus envelope re- 
gion (hatched box) are indicated. 
LTR,  long tandem repeat; t~+, 
packaging signal. 
tively). Lane 3 represents cell lysate from patient C.M. after 
transduction with  SAM-EN control retroviral  vector con- 
taining  only  the  neomycin  resistance  gene  (neo).  GCJ3- 
transduced  cells  were  shown  to  newly  express JAK3 pro- 
tein of expected molecular weight and at levels comparable 
to controls. Cells transduced with the control vector carry- 
ing  only neo  did  not  show increased  expression  of JAK3. 
The  filter  was  stripped  and  reprobed  with  ot-JAK1  (lower 
panel)  to verify equal loading in all lanes.  These data dem- 
onstrate  that in vitro gene delivery using retroviral vectors 
is an efficient method to restore high levels of expression of 
JAK3 protein in cells from JAK3-SCID patients. 
JAK3  PhosphorylationAnalysis.  To  examine  whether  the 
expression  of  JAK3 would restore  cytokine responsiveness 
in  transduced  cells,  we  analysed  IL-2-  and  IL-4-induced 
phosphorylation of  JAK3 (Fig. 3, top). Normal donor BCLs 
(lanes  1-3),  untransduced  (lanes  4-6),  and  JAK3-trans- 
duced  (lanes  7-9)JAK3-SCID  patient  cells  were  left  un- 
stimulated (lanes  1, 4, and  7) or stimulated with IL-2 (lanes 
2,  5, and  8),  or IL-4 (lanes  3,  6, and  9).  Lysates were im- 
munoprecipitated  with  ot-JAK3  and  immunocomplexes 
probed with ot-PY. We observed that the transduced JAK3 
protein  was  properly  phosphorylated  in  response  to  both 
cytokines,  thus  demonstrating that the signal generated by 
IL-2 and IL-4 ligand binding was appropriately transduced 
to the newly expressed JAK3 protein.  The filter was then 
stripped  and  reprobed  with  oL-JAK3  to  confirm the  pres- 
ence  of JAK3  protein  in  the  immunoprecipitates  (Fig.  3, 
bottom).  As  expected  from the  absence  of JAK3  in  whole 
cell lysate  (Fig.  2, lane  2),  no JAK3 protein was immuno- 
detected  in  the  JAK3-SCID  cells  before  gene  transfer 
(lanes  4-6).  Taken  together these  data further suggest that 
Figure  2.  Analysis  of JAK3 protein expression. Lysates of BCLs ob- 
tained from normal control (lane 1), JAK3-SCID patient C.M. untrans- 
duced (lane 2) and transduced with neo (lane 3)  or with JAK3 cDNA 
(GCJ3, lane 4), and JAK3-SCID patient C.A. untransduced (lane 5) or 
transduced with JAK3 cDNA (lane 6) were subjected to SDS-PAGE and 
then electro-transferred to nylon filter. The membrane was immunoblot- 
ted (IB) with cl-JAK3 (top), then stripped and reblotted with ~x-JAK1 (bot- 
tom) to veil@ equal loading. 
Figure 3.  Analysis  ofJAK3 phosphorylation.  Normal control (lanes I-3), 
untransduced (4-6) and GCJ3-transduced (lanes 7-9)  JAK3-SCID BCLs 
were stimulated with the indicated cytokine for 15 rain at 37~  lysed, 
and immunoprecipitated (IP) with 0t-JAK3. Complexes were resolved by 
SDS-PAGE and detected by immunoblotting (IB) with ot-PY. Membrane 
was stripped and the presence of  JAK3 in immunocomplexes  was verified 
by blotting with ot-JAK3. 
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Figure 4.  Effects  of IL-2 on cell proliferation.  BCLs were stimulated 
for 30 h with IL-2 and proliferation,  determined  by DNA incorporation 
of tritiated thymidine,  indicated as stimulation index (ratio between aver- 
age incorporated  [3H]-Tdr in the presence of IL-2 to that in the absence 
of IL-2).  Cpm values in RPMI medium without  IL-2  were as follows 
(average +  SD): normal BCLs, 2,748  +  207; patient  C.M.,  1,239 -- 91; 
patient  C.M. transduced  with  neo,  960  +  72; patient  C.M.  transduced 
with GCJ3,  1,087 4- 83. 
the transduced gene product was capable of  functionally as- 
sociating with %, thus restoring the JAK3-',/c interaction, a 
critical component of signaling  through  all y~-containing 
receptors (11). 
IL-2-mediated  Cell Proliferation.  Previous  studies  (29,  30) 
have indicated a primary role for JAK3 in cell proliferative 
response to IL-2, thus suggesting the involvement of  JAK3 
in  IL-2-induced  cell  cycle progression  mechanisms.  The 
results  of these studies would predict a defective prolifera- 
tive response to IL-2 in cells from JAK3-deficient patients. 
To determine whether JAK3-SCID BCLs showed reduced 
proliferation in response to IL-2 and whether JAK3  gene 
transfer and expression could restore a normal response, we 
assayed  IL-2-induced  cell  proliferation  before  and  after 
gene transduction. We previously determined appropriate 
culture conditions that allowed us to demonstrate a specific 
proliferative response of BCLs  to  IL-2  (27).  Using  these 
same conditions, we could detect substantially reduced cell 
proliferation ofJAK3-SCID BCLs to IL-2 when compared 
to normal donor BCLs. Moreover, we demonstrated nor- 
realization of IL-2-mediated cell growth after JAK3  gene 
transfer  (Fig.  4),  but  not  after transduction  with  the  neo 
control  retroviral vector.  It  should  be  noted  that  EBV- 
immortalized B  cell lines are not IL-2 growth dependent, 
and therefore the effect oflL-2 on cell growth is not as dra- 
matic  as  it is  for primary cells  or factor-dependent lines. 
Nonetheless, lack of proliferation to IL-2 in JAK3-SCID 
cells confirms the importance of  JAK3 for cell cycle pro- 
gression induced by this cytokine. Furthermore, the resto- 
ration of an appropriate proliferative response upon  gene 
correction  demonstrates  that  the  exogenously  expressed 
JAK3 protein allowed for proper transduction of the IL-2 
signal  from receptor to nucleus, leading to transcriptional 
activation  of specific  genes  responsible  for  cell  growth. 
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Moreover, the generation of gene-corrected JAK3-SCID 
cells will be of considerable importance in further analysis 
of general  pathways  of cytokine  signaling  where  JAK3 
kinase is involved (Oakes, S.A., F. Candotti, J.A. Johnston, 
J.J.  Ryan,  N.  Taylor, L.  Henninghausen,  L.D.  Notaran- 
gelo, W.E. Paul, R.M. Blaese, and J.J.  O'Shea, manuscript 
in preparation). 
Severe  combined  immunodeficiencies are  a  heteroge- 
neous group of inherited disorders of immunity character- 
ized by failure to thrive, severe infections, and combined 
lack of T  and B cell functions. Infectious episodes are usu- 
ally  recurrent, life-threatening, and lead to  death in  early 
life unless affected patients undergo reconstitution of a nor- 
mal immune system by allogeneic bone marrow transplan- 
tation (31).  Transplantation procedures from HLA-identi- 
cal siblings  usually result in full immune reconstitution of 
the recipients with minimal risks related to GVHD. In con- 
trast, transplantation from haplo-identical donors or MHC- 
matched unrelated individuals is characterized by a higher 
risk of severe GVHD and graft failure (21, 32). Gene ther- 
apy, therefore, could represent a beneficial alternative form 
of treatment for those patients lacking a  suitable  marrow 
donor. 
The recent identification of defects in JAK3 protein ex- 
pression  as  the  cause  of an  autosomal  recessive  form  of 
SCID  (19,  20) has on the one hand opened the way for a 
better understanding of the mechanisms involved in lym- 
phocyte development and differentiation, and on the other 
provided the basis for investigating gene-based therapeutic 
approaches. We demonstrate here that retroviral-mediated 
gene transduction could effectively correct several biologi- 
cal defects in B  cell lines from JAK3-SCID  patients. Be- 
cause  of the lack  of mature  circulating T  cells,  these pa- 
tients  are  not  eligible for a  T  lymphocyte-directed gene 
transfer approach as previously used for adenosine deami- 
nase-deficient  SCID  (33);  consequently,  corrective  gene 
transfer for JAK3-deficient patients will require targeting of 
the  lympho-hematopoietic  stem  cell.  Retroviral  vectors 
have been demonstrated capable of safely transferring and 
expressing exogenous genes into hematopoietic progenitors 
in animal models  (34-36) and humans  (37-39).  It is con- 
ceivable, therefore, that the genetic correction and reinfu- 
sion  of autologous JAK3-deficient lympho-hematopoietic 
stem  cells  could provide a means  to reconstitute the  im- 
mune system of  JAK3-SCID patients, avoiding the risks of 
GVHD. 
Further studies are necessary to assess whether the  "ec- 
topic" expression of retrovirally transduced JAK3 in a stem 
cell  could be  deleterious to  the  normal  development  of 
non-lymphoid  hematopoietic  lineages  before  a  clinical 
gene therapy protocol for JAK3-SCID could be proposed. 
As  part  of pre-clinical  investigations,  the  transfer  of the 
JAK3 gene into the hematopoietic system of animal models 
would provide important insight into the biological effects 
of the exogenous expression of  JAK3 protein. The recent 
generation of mice with a  targeted deletion of the JAK3 
gene (40-42)  constitutes an important model where these 
critical issues can be conveniently addressed. 
Gene Therapy for  JAK3-deficient Severe Combined Immunodeficiency Furthermore, the definition of the JAK3 genomic struc- 
ture (Riedy, M.C., W. Modi, A.S. Dutra, T.B, Blake, B.K. 
Lal, J.  Davis,  A.  Bosse, J.J.  O'Shea,  and  T.A.  Johnston, 
manuscript submitted for publication) and the future iden- 
tification of its regulatory region will provide the possibility 
of constructing gene transfer vectors containing the natural 
promoter  sequences  and  leading  to  physiologically con- 
trolled JAK3 expression. 
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